- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01231945
Low-Cost Molecular Cervical Cancer Screening Study
Background:
- Low-cost molecular human papillomavirus (HPV) testing may offer a more robust alternative to Pap smears and visual inspection for cervical cancer screening of underserved women. Two low-cost molecular tests for human HPV, the HPV E6 Test and the careHPV test, have been developed to detect cervical cancer by testing for HPV DNA. These tests take between 2 and 3 hours to run and may provide point-of-care (diagnostic testing at or near the site of patient care) testing for HPV. Researchers are interested in evaluating both tests to determine the best strategy for HPV testing of women who live in rural or underserved areas that have a high prevalence of cervical cancer diagnoses.
Objectives:
- To evaluate the clinical performance of the HPV E6 Test and careHPV in detecting cervical cancer and precancerous lesions.
- To evaluate the best low-cost test or combination of tests for women who have been referred for cervical cancer screening or treatment.
- To compare the clinical performance of self-collected specimens versus clinician-collected specimens in detecting cervical cancer and precancerous lesions.
Eligibility:
- Women between 25 and 65 years of age who live in rural China.
Design:
- This study involves an initial testing visit and a 1-year followup visit for a high-risk subgroup.
- Participants will have the HPV E6 test, careHPV, and a visual inspection test for cervical cancer. For comparison, participants will also have the standard HPV test approved by the U.S. Food and Drug Administration.
- Participants who test positive for HPV on any of the above tests will also have colposcopy to collect samples of cervical tissue for further study.
- A random sample of women who test negative for HPV will also have colposcopy. Participants may also have biopsies if there is visual evidence of cervical abnormalities.
- At the 1-year followup visit, participants in the high-risk subgroup will have the same tests as in the previous visit..
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China
- CICAMS
-
-
-
-
Washington
-
Seattle, Washington, United States
- PATH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA:
- have not been previously diagnosed with cervical cancer
- have a cervix
- are not pregnant
- are physically able to undergo routine cervical cancer screening 5) are able to provide informed consent
- We will not exclude women if they have had previous cervical cancer screening because we assume that even if a few women have been screened for cervical cancer, the quality of cytology screening was very poor.
EXCLUSION CRITERIA:
1) are not married AND report never having had sexual intercourse 2) have had a total hysterectomy
3) have a history of cervical cancer
4) are physically or mentally unable to undergo routine cervical cancer screening or unable to provide informed consent.
5) are pregnant or have been pregnant in the last month
-Women who are currently menstruating at the time of enrollment will be deferred from participating, and will become eligible to participate 7-14 days after menstruation has ended. The menstruating women will be advised to return for the screening 7 to 14 days after their menstrual period has concluded.
Study Plan
How is the study designed?
Design Details
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108. doi: 10.3322/canjclin.55.2.74.
- Munoz N, Castellsague X, Berrington de Gonzalez A, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006 Aug 31;24 Suppl 3:S3/1-10. doi: 10.1016/j.vaccine.2006.05.115. Epub 2006 Jun 23.
- Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006 May;110(5):525-41. doi: 10.1042/CS20050369.
- Zhao FH, Jeronimo J, Qiao YL, Schweizer J, Chen W, Valdez M, Lu P, Zhang X, Kang LN, Bansil P, Paul P, Mahoney C, Berard-Bergery M, Bai P, Peck R, Li J, Chen F, Stoler MH, Castle PE. An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in rural China. Cancer Prev Res (Phila). 2013 Sep;6(9):938-48. doi: 10.1158/1940-6207.CAPR-13-0091. Epub 2013 Jul 22.
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 999911015
- 11-C-N015
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uterine Cervical Neoplasms
-
Huazhong University of Science and TechnologyChongqing University Cancer Hospital; Peking University People's Hospital; Qilu... and other collaboratorsRecruitingCervical Cancer | Uterine Cervical Cancer | Uterine Cervical NeoplasmChina
-
Huazhong University of Science and TechnologyUnknownCervical Cancer | Uterine Cervical Cancer | Uterine Cervical NeoplasmChina
-
Huazhong University of Science and TechnologyQilu Hospital of Shandong University; Third Military Medical University; Women... and other collaboratorsRecruitingCervical Cancer | Uterine Cervical Cancer | Uterine Cervical NeoplasmChina
-
Huazhong University of Science and TechnologyZhejiang University; Wuhan Central HospitalUnknownCervical Cancer | Uterine Cervical Neoplasms | Uterine Cervical CancerChina
-
Washington University School of MedicineTerminatedCervical Cancer | Uterine Cervical Neoplasms | Uterine Cervical CancerUnited States
-
University of AarhusRecruitingUterine Cervical Neoplasm | Mass Screening | Uterine Cervical Disease | Uterine NeoplasmDenmark
-
Siriwan Tangjitgamol, MDPrince of Songkla University; National Research Council of Thailand; Chiang Mai... and other collaboratorsUnknownUterine Cervical CancerThailand
-
Tampere UniversityGlaxoSmithKline; FinnMedi OyEnrolling by invitation
-
University Hospitals Cleveland Medical CenterCompletedUterine Cervical Dysplasia | Uterine Cervical Cancer | Uterine Cervical Neoplasia | Uterine Cervical Intraepithelial Neoplasia
-
Huazhong University of Science and TechnologyShandong University; Zhejiang UniversityCompletedCervical Cancer | Uterine Cervical Neoplasms | Uterine Cervical CancerChina